StockLearn from Clustermicro · Stock Breakout ScannerStockLearn

Abbott India (ABBOTINDIA)

Pharma · NSE · end-of-day 2026-10-19

₹25,905.00

Day change

-1.01%

1-year

-12.7%

From 52-week high

-14.4%

Weinstein stage

Stage 1

Minervini template

1/8

Abbott India closed at ₹25,905.00 on 2026-10-19, down 13% over the past year, 14% below its 52-week high. It meets 1 of 8 conditions of Minervini's trend template; Weinstein's stage analysis reads stage 1 - basing; on earnings, it passes 1 of 3 SEPA checks. Over the year its annualised volatility was about 20%, with a largest fall of 17% from a peak.

About Abbott India

Abbott India Limited manufactures and markets branded pharmaceuticals, nutritional products, diagnostic solutions, and healthcare products across multiple therapeutic categories. The company benefits from the global research, innovation, and product portfolio of Abbott Laboratories. Strong brand recognition among healthcare professionals supports market leadership. Product innovation and healthcare awareness continue to expand demand. India's growing pharmaceutical market remains a long-term growth opportunity.

Price, RSI and MACD

6M1Y2Y3Y

Price · +1.4% over the period

RSI (14) · 44.8

MACD (12, 26, 9) · histogram -35.45

Price · -14.0% over the period

RSI (14) · 44.8

MACD (12, 26, 9) · histogram -35.45

Price · -7.8% over the period

RSI (14) · 44.8

MACD (12, 26, 9) · histogram -35.45

Price · +14.1% over the period

RSI (14) · 44.8

MACD (12, 26, 9) · histogram -35.45

Price: daily close adjusted for splits and bonuses, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.

Fundamentals

Market cap	Sales (TTM)	Net profit (TTM)	P/E	EPS (TTM)	P/B	ROE	Beta
₹54,663 cr	₹7,004 cr	₹1,615 cr	34.1	759.85	11.53	33.8%	0.25

Quarterly results

Quarter	Sales ₹ cr	Net profit ₹ cr	EPS	EPS YoY	Sales YoY	Net margin
Jun 2026	1,814	428	201.66	+17.1%	+4.3%	23.6%
Mar 2026	1,710	395	185.85	—	—	23.1%
Dec 2025	1,724	376	176.92	—	—	21.8%
Sep 2025	1,757	415	195.42	—	—	23.6%
Jun 2025	1,738	366	172.17	—	—	21.1%

Standalone · EPS restated onto today's share count after splits and bonuses · net profit as filed.

Minervini SEPA — earnings checks 1 of 3 pass

Check	Result
Latest quarter EPS up 25%+ on a year ago	✗ Fail
EPS growth accelerating over 3 quarters	— Not assessable
Sales up 25%+, or sales growth accelerating	✗ Fail
Annual EPS up 25%+ in each of the last 2 years	— Not assessable
Net margin above the same quarter last year	✓ Pass

Investor methods

Method	Checks	Score	Verdict
Minervini	✗ Close above the 150- and 200-day averages ✗ 150-day above 200-day ✗ 200-day rising for a month ✗ 50-day above the 150- and 200-day ✗ Close above the 50-day ✗ At least 25% above the 52-week low · low 25,180.00 ✓ Within 25% of the 52-week high · high 30,255.00 ✗ RS percentile 70 or more · RS 37 Trend template - the gate, measured: a modest 21-day edge.	1/8	1 of 8
Weinstein	Stan Weinstein's stage analysis on the 30-week moving average.		Stage 1 - basing
CAN SLIM	✗ C latest quarter EPS up 25%+ — A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✓ N within 15% of the 52-week high · high 30,255.00 ✗ S more volume on up days than down days (50 sessions) · 0.71x ✗ L RS percentile 80 or more · RS 37 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist.	2/5	Weak
Darvas	✗ New 52-week high in the last 120 sessions Darvas needs a new 52-week high to start a box.	10/100	No box
Turtle	✗ Close above the prior 55-session high · 28,635.00 ✗ Close above the prior 20-session high · 27,850.00 ✗ Close below the prior 20-session low · 25,475.00 Donchian channel breakout - the Turtle traders' entry.		No signal
Graham	✗ Price at or below the Graham number · Graham number 6,197.73 ✗ P/E 15 or less · P/E 34.1 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 11.53 — Current ratio 2 or more — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests.	24/100	Expensive

Each method's own rules applied to this stock - information, not a buy or sell signal. All were tested on 2024-26 data; only the Minervini trend template showed a consistent edge.

Pharma sector — top 10 by 1-year return

Stock	1M %	3M %	6M %	1Y %	3Y %	5Y %	P/E	P/B	ROE %	ROCE %	ROA %	D/E	EV/EBITDA	₹ Cr	Sales TTM ₹ Cr	Profit TTM ₹ Cr	EPS	Beta
ABBOTINDIA this stock	-5.0	-8.4	+1.4	-13.1	+14.3	+25.9	34.1	11.53	33.8	—	—	—	—	54,663	7,004	1,615	759.9	0.25
BLISSGVS	-8.0	+29.9	+147.2	+312.3	+606.5	+476.9	48.7	5.57	11.5	16.8	—	0.00	29.3	6,650	1,005	142	12.9	1.10
VENUSREM	+0.7	-5.9	+55.8	+252.6	+518.8	+242.4	18.3	3.21	16.8	21.9	—	0.00	13.7	2,130	811	116	86.9	0.88
INDSWFTLAB	-5.7	+50.4	+153.3	+247.2	+287.1	+472.2	51.6	2.21	3.2	3.9	—	0.01	33.4	3,056	665	57	6.8	0.78
MOREPENLAB	+0.5	+108.6	+194.2	+152.6	+242.7	+132.7	47.5	5.34	7.9	10.1	—	0.16	40.2	6,657	1,951	140	2.6	1.46
SHILPAMED	-14.2	+40.1	+113.1	+146.1	+421.3	+189.7	57.3	6.61	9.8	11.4	—	0.25	—	17,130	1,682	297	15.3	0.87
RUBICON	-15.1	-1.7	+60.3	+140.3	—	—	83.8	19.08	22.4	—	—	0.20	61.3	24,587	1,936	288	17.7	0.34
LAURUSLABS	+5.9	+32.7	+83.2	+129.9	+421.9	+235.3	88.9	21.09	18.2	17.9	—	0.45	62.0	1.12L	8,839	1,252	23.3	0.74
ZIMLAB	+2.0	+14.2	+73.3	+101.9	+17.5	—	168.5	2.50	2.1	5.5	—	0.42	21.1	740	397	4	0.8	0.75
ACUTAAS	-5.4	-11.0	+35.0	+97.5	—	—	69.0	16.11	24.0	31.7	—	0.02	49.9	26,636	1,462	387	47.2	0.77
IOLCP	-9.8	+17.8	+108.9	+87.8	+99.0	+56.2	32.0	2.99	7.9	10.7	—	0.07	20.7	5,376	2,524	168	5.7	1.13

A blank in a return column means the stock is younger than that window. P/B and ROE come from each company's own filings where held.

Pharma stocks of a similar size

Biocon Alkem Laboratories Gland Pharma Glenmark Pharma IPCA Laboratories Anthem Biosciences Limited GSK Pharma Ajanta Pharma

The live scanner - every stock ranked, filtered by method, stage and sector, with interactive charts - is in the StockLearn app. Open the StockLearn scanner →

Prices as of 2026-10-19, end of day, from NSE. Fundamentals from each company's own exchange filings (XBRL), EPS restated for splits and bonuses. Figures may be delayed and are for information only.

For research & education only — not investment advice. The methods, checks and verdicts are automated rules applied to public data, not buy/sell recommendations. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by the NSE or any exchange. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.

Terms · Privacy · Disclaimer · Refund · Contact